Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Key points are not available for this paper at this time.

Awasthi et al. (2015) studied this question.

View Full Paper

Ask AI

Bookmark